HIMS Earnings
Monday, May 04 2026
EPS Estimate
$0.14
$0.08 – $0.18
Revenue Estimate
$616M
Track Record
3/4 beats
Current Price
$31.01
Our Position
bullish · highHims & Hers jumps 11% on FDA peptide move
est. revisions rising
(+114.3pp / 30d)
FDA's peptide policy changes could unlock new revenue streams and modify HIMS's regulatory risk profile, impacting its telehealth peptide business significantly.
Watch: FDA peptide policy decision in July 2026 for commercial and regulatory clarity impacting HIMS's compounded peptide treatments.
Data Signal Summary
4 bullish
1 bearish
Estimates up +32%
Put/call 0.3 (bullish skew)
Analysts: bullish
Price uptrend
Insider selling
Key Context
Analyst Consensus
bullish
Insider Activity
selling
Price Trend
uptrend
1-Month Return
+15.4%
From 52w High
-56.5%
P/E Ratio
60.8
Est. Revisions (30d)
+31.5% 0up/0dn
Analyst Target (mean)
$24 $16–$30 -22%
Options P/C Ratio
0.32 13C/12P unusual
Est. Dispersion
470% 10 analysts
Fund Convergence
strong Citadel, Renaissance, D.E. Shaw, Bridgewater
Recent Activity
insider trades
5 transactions
Other
·
DUDUM ANDREW (Chief Executive Officer)
·422,933 shares
Sell
·
OKUPE OLUYEMI (Chief Financial Officer)
·3,975 shares
·$79,409
Exercise
·
OKUPE OLUYEMI (Chief Financial Officer)
·3,975 shares
·$19,915
Sell
·
OKUPE OLUYEMI (Chief Financial Officer)
·9,217 shares
·$219,067
Exercise
·
OKUPE OLUYEMI (Chief Financial Officer)
·4,489 shares
·$22,490
analyst ratings
1 rating
B of A Securities
→Neutral
4d ago
ae trade
7
4d ago
5d ago
8d ago
Explore more
